Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 6Colorectal Neoplasms 4Neoplasms 3Uterine Cervical Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Hepatocellular Carcinoma (HCC) 1Adenocarcinoma Of Esophagus 1Acrocephalosyndactylia 1

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × brivanib × Clear all
NCT01253668 2021-04-13

Brivanib Metastatic Renal Cell Carcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡